Navigation Links
Cell-based therapy shows promise in patients with Parkinson's disease
Date:4/28/2008

ary for the cells to survive in the brain. The implanted cells serve as a new potential source of levodopa to enhance dopamine production where it is most needed.

The patients were selected based on disease stage, levodopa responsiveness, and severity of PD symptoms while off medication. An even distribution of Spheramine was surgically implanted into the more affected side of the brain, and patients left the hospital a few days later.

The primary efficacy measure in this trial is the motor score of the Unified Parkinsons Disease Rating Scale (UPDRS) when the patient has been OFF antiparkinsonian medication for at least 12 hours. The researchers report clinical improvements were noted in both UPDRS motor scores off medication (44 percent improvement from baseline at 48 months) and patient-reported quality of life scores (23 percent improvement from baseline of total PDQ-39 score at 48 months). Several of these patients have been monitored for 6 years and the trial has been extended to 10 years of follow-up.

Bakay said positive results in the pilot study prompted the initiation of a Phase IIb, multicenter, double-blind, randomized, sham surgery-controlled study (STEPS) to further evaluate the safety, tolerability and efficacy of Spheramine. Changes from the pilot study included implantation in both sides of the brain and the addition of a sham surgery group. To date, 71 patients have been randomized for either Spheramine or sham surgery and results from the will become available later this year.

Parkinsons Disease

Parkinsons disease is a progressive brain disorder that affects a persons motor skills which worsen as the disease advances. Early in the disease, there is a loss of brain cells that produce the chemical dopamine. Normally, dopamine operates in a delicate balance with other neurotransmitters to help coordinate the millions of nerve and muscle cells involved in movement. Without enough dopamine, thi
'/>"/>

Contact: Mary Ann Schultz
mary_ann_schultz@rush.edu
312-933-7333
Rush University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Challenges and promise of cell-based therapies
2. Genetic Engineering & Biotechnology News reports on growing use of cell-based assays
3. A new radiation therapy treatment developed for head and neck cancer patients
4. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
5. UC health news: molecular pathway may predict chemotherapy effectiveness
6. MIT works toward safer gene therapy
7. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
8. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
9. Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases
10. Safe and effective therapy discovered for patients with protein-losing enteropathy
11. Ireland Cancer Center researchers advance stem cell gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
(Date:4/27/2015)... -- For more than four decades, AUVSI,s Unmanned Systems ... worldwide event for the unmanned land, sea, and air ... any local, national, or trade news organization interested in ... current applications of unmanned technologies. The conference will explore ... industry, and how it will soon impact the lives ...
(Date:4/27/2015)... 27, 2015 Profile Solutions, Inc. (OTC: PSIQ), ... systems is pleased to announce that Dr Gerry ... and member of its scientific advisory board. ... a thought leader in technology-enhanced learning models. He was ... has published studies and books focused on online student ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... 19, 2009Scientists say they are forging ahead in developing ... renewable while having a minimal impact on the environment, ... A consensus is emerging that no one technology will ... novel methodologies will contribute to meeting biofuel needs, according ...
... Swiss Institute of Bioinformatics today announced the winners of the ... Award at the 7th annual [BC]2 Basel Computational Biology Conference. ... The winner of the 2009 SIB Young Bioinformatician Award is ... the past four years with the SIB in the Bioinformatics ...
... of Cordell Bank National Marine Sanctuary indicates that the ... is fair to good, but identifies several emerging threats ... as marine debris, ocean acidification and invasive species have ... said Dan Howard, sanctuary superintendent. "This report provides a ...
Cached Biology News:The SIB recognizes the next generation of bioinformaticians 2The SIB recognizes the next generation of bioinformaticians 3NOAA report finds threats to California's Cordell Bank Marine Sanctuary 2
(Date:5/28/2015)... 2015 Biscayne Pharmaceuticals, Inc ., today ... growth hormone-releasing hormone (GHRH) technology will be discussed in a ... Meeting. The data show that the family of receptors ... is present on many primary breast cancer cells regardless ... antagonists could have broad anti-cancer potential in breast cancer. ...
(Date:5/28/2015)... 28, 2015 CD-adapco, the largest ... software, announced today it is joining the consortium ... provide state-of-the-art engineering simulation tools for analyzing particle ... and experiences in analyzing particle flow that will ... advance the understanding of flow modeling solutions. , ...
(Date:5/28/2015)... Sunnyvale, Californiaa (PRWEB) May 28, 2015 ... on “ The Changing Landscape of EMR/EHR Clinical Data ... Annual Meeting taking place in Washington, DC on June ... the challenges of integrating EMR/EHR systems with EDC, and ... the opportunities brought by eSource and electronic health records/electronic ...
(Date:5/28/2015)... Minneapolis, MN (PRWEB) May 28, 2015 ... makes it a point to ask his audiences ... of future trends including robotics, solar cells, fuel ... sequencing, 3D printers, advanced battery storage technology, driverless ... assistants, and high-quality but inexpensive online education. ...
Breaking Biology Technology:Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2Futurist Jack Uldrich to Deliver 4 Keynote Addresses in June 2
... and UNION CITY, Calif., June 2 Santen,Pharmaceutical ... the two,companies have entered into a research and ... Asian development and,commercialization of sirolimus for the treatment ... macular degeneration (wet AMD) and,diabetic macular edema (DME). ...
... of All Evaluable Patients in Phase I Study Receiving Combination of, Bavituximab Plus ... ... - 100% of Evaluable Patients to Date in Ongoing Phase II ... or Stable Disease -, CHICAGO and TUSTIN, Calif., June 2 Peregrine,Pharmaceuticals, ...
... 2 SAFC Hitech(TM), a focus,area within SAFC(R), ... SIAL ),today announced the introduction of the OM700, ... to controlled precursor delivery,for larger lot sizes, enabling ... controls., The OM700 offers reliable and very ...
Cached Biology Technology:Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions 2Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions 3Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study 2Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study 3Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study 4Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study 5SAFC Hitech Introduces Large Scale Bubbler for Compound Semiconductor Production 2SAFC Hitech Introduces Large Scale Bubbler for Compound Semiconductor Production 3